Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

Table 4 Clinical response of metastatic colorectal cancer patients

Response	Total (n = 313)		F (n = 70)		R (n = 67)		FP (n = 95)		RP (n = 81)
	n	%	n	%	n	%	n	%	n	%
PR	22	7.0	3	4.3	4	6.0	11	11.6	4	4.9
SD	189	60.4	39	55.7	37	55.2	60	63.1	53	65.5
PD	102	32.6	28	40.0	26	38.8	24	25.3	24	29.6
ORR	22	7.0	3	4.3	4	6.0	11	11.6	4	4.9
DCR	211	67.4	42	60.0	41	61.2	71	74.7	57	70.4

PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate; F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.